Combination of small molecule CD-47 inhibitors with other anti-cancer agents

1. A composition comprising a CD47-SIRPα blocking agent and one or more anti-cancer agent(s): wherein the CD47-SIRPα blocking agent is selected from the group consisting of:

Compound

Structure

 1

 2

 3

 4

 5

 6

 7

 8

 9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

or a pharmaceutically acceptable salt or an amide or an ester, or a stereoisomer thereof.

2. The composition of claim 1 , wherein the anti-cancer agent is a chemotherapeutic agent, or an immunomodulatory agent.

3. The composition of claim 2 , wherein the chemotherapeutic agent is azacitidine or a proteasome inhibitor (bortezomib, ixazomib and carfilzomib).

4. The composition of claim 2 , wherein the immunomodulatory agent is a costimulatory molecule or a coinhibitory molecule comprising antibodies to PD-1 and PD-L 1 (e.g., nivolumab, pembrolizumab, atezolizumab, Durvalumab and Camrelizumab).

5. The composition of claim 1 , wherein the anti-cancer agent is a therapeutic antibody targeting tumor antigens that stimulate activating Fc receptors (FcRs).

6. The composition of claim 5 , wherein the therapeutic antibody is selected from the group capable of triggering efficient phagocytosis comprising anti-CD20 (rituximab, tiuxetan, and tositumomab).

7. A pharmaceutical composition comprising CD47-SIRPα blocking agent and one or more anti-cancer agent(s) as claimed in claim 1 , and a pharmaceutically acceptable carrier.

8. A method for treating or delaying progression of diseases or disorders mediated by dysregulated CD47-SIRPα pathway in a subject, the method comprising administering to the subject in need thereof a therapeutically effective amount of a CD47-SIRPα blocking agent of claim 1 in combination with a therapeutically effective amount of one or more anti-cancer agent(s).

9. The method of claim 8 , wherein the subject presenting a dysregulated CD47 pathway is a subject presenting with CD47+ disease cells.

10. The method of claim 8 , wherein the disease or disorder is cancer mediated by dysregulated CD47-SIRPα pathway.

11. The method of claim 10 , wherein the cancer is selected from melanoma, renal cancer, prostate cancer, breast cancer, colon cancer and lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, non-Hodgkin's lymphoma, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemias including acute myeloid leukemia, acute lymphocytic leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, solid tumours of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), non-small cell lung cancer (NSCLC), primary CNS lymphoma, tumour angiogenesis, spinal axis tumour, brain stem glioma, pituitary adenoma, Kaposi's sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, B-cell lymphomas, myeloproliferative disorder/neoplasm (MPDS); myelodysplastic syndrome; giant cell myeloma, heavy-chain myeloma, light chain myeloma and Bence-Jones myeloma, multiple myeloma, environmentally induced cancers including those induced by asbestos (e.g., mesothelioma), and combinations of said cancers.